請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20187
標題: | 美商必帝醫療器材公司購併策略分析 Study of M&A Strategy : Becton Dickinson & C.R. Bard |
作者: | Miao-Fen Fong 馮妙芬 |
指導教授: | 黃崇興 |
關鍵字: | 生技產業,醫療器材,購併,策略分析,綜效, bio-tech industry,medical device,merge and acquisition,strategic analysis,synergy, |
出版年 : | 2018 |
學位: | 碩士 |
摘要: | 生技發展一直是前膽性的產業,造福大眾,也刺激商業活動。產品的研發耗時冗長,研發經費高,成功率無法預期,所以在整個產業上,併購成了最快達成目楆的商業活動之一。舉凡藥品所關連之專利,或者多階段人體試驗計劃,藥品上市時間更是漫長等待,醫療器材產業亦同。
跨國企業要成長,除了市場穩定的自然成長外,引進新產品則是另一個可以快速提昇成長的機會,但由於醫療器材牽涉到人體健康,所以產品上市前之多次的安全測試,檢視留置體內時間或其他相關,研發時間久。而除了產品研發期耗時久外,另外則是各國皆有自已國家的醫療法規把關新產品的進入各國,所以各國法規的審查也是延後產品上市的時間。 基於此,愈來愈多的醫藥跨國企業朝向另個商業行為,選擇收購整併其他公司,縮短研發期。本研究個案以美商BD 公司為例,一個百年的公司,全球醫療器材排名第9大的公司,購併另一個全球第24大之百年醫療公司,美國BARD公司。併購前後的經營方向,策略分析,綜效研討, 並也探討對創業者,或其他未來醫療器材公司選併公司時的參考及其建議。 The medical device is one of the biggest industries in healthcare categories driven by innovation and new technologies. With the social change, the overall population structure tends to age, people need efficient device to care their health strongly. How to make medical device company grow despite of natural growth? Ideally, to have a new product would be the quickest way to achieve the quota, and get the better performance. But in reality, a new innovative product lunch is not easy, the R&D takes times to get the product ready, follow by taking several years to pass the human trial. If luckily, everything is done, the manufacturers would be busy to prepare the bunch of documents for individual countries for registration. Therefore, merge and acquisition would become an alternative project for company growth. It becomes a trend for M&A activities in medical industries, for both pharmaceutical companies and medical device companies. This study is aimed at one global medical technology US company, Becton Dickinson, which has well established for 120 years in market, merge with another well-known US company, C.R. BARD. BD leads in both healthcare workers and patient safety and provides the innovative solutions for advance medical research and promotes infection prevention. BARD is specialized excellent at disease management. This agreement was just made and did not read any benefits from this acquisition yet, but we can still study these well-established company historical paths, market strategies and positions. The case study shows the growth of this smart acquisition and also provides the other medical companies for further reference. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20187 |
DOI: | 10.6342/NTU201800376 |
全文授權: | 未授權 |
顯示於系所單位: | 商學組 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 2.81 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。